Moderna $MRNA Surges 90% on Melanoma Vaccine Win With Merck

$MRNA just had its best single-day performance on record, surging roughly 90% in pre-market before settling around a 135% gain at various intraday peaks, depending on which Bloomberg anchor you were watching. The catalyst: a Phase 3 trial combining Moderna's individualized mRNA-based cancer therapy with $MRK's Keytruda immunotherapy showed the treatment successfully prevented melanoma from returning or spreading in high-risk surgical patients. That's not a small deal. That's the mRNA platform proving it can do more than COVID boosters.

Here's how the math worked on the day. $MRNA closed up approximately 70%, adding over $43 per share to land around $107.30. $MRK had a quieter but still meaningful 5.8% gain, picking up roughly $8.25. The asymmetry makes sense: Keytruda is already a blockbuster franchise for Merck, so this is gravy. For Moderna, it's the entire argument for why the company survives post-pandemic. Partner biotech Arcturus also caught heat from the news, rising on broader mRNA sentiment.

The bear case, and Bloomberg was politely aggressive about this: analysts flagged that significant short covering was likely amplifying the move. Moderna has been one of the most-shorted stocks in biotech for the past two years, so a genuine positive catalyst in a heavily shorted name is basically a rocket ship with extra fuel. The question is whether the fundamental thesis holds once the shorts are washed out. A personalized cancer vaccine is extraordinarily complex and expensive to manufacture at scale, and commercialization timelines in oncology are never as clean as a Phase 3 press release makes them look.

The bull case is that the mRNA platform now has a second major validated use case. If melanoma works, the pipeline logic for other solid tumors becomes more credible. Moderna's revenue run rate has been a problem since COVID demand cratered, and this gives the street a new growth narrative to model. Watch for updated analyst price targets in the next 48 hours, because most models going into Thursday were not pricing in this outcome.

Deere also reported during the week, with quarterly net sales hitting $122.6 billion and full-year net income guidance raised to a $4.75 to $5 billion range despite absorbing $1.1 billion in tariff headwinds. Solid execution in a tough macro, which at least tells you farm equipment demand hasn't completely rolled over. Small ag and construction held up better than expected.

When a company's best day ever is partly driven by a short squeeze, you don't celebrate, you audit. But you also don't ignore a Phase 3 win just because the trade was crowded.